Skip to main content
Signal8
Launch Terminal

Ocugen, Inc. (OCGN)

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Ocugen, Inc. logo

Ocugen, Inc.

NASDAQ:OCGNHealthcare
-5.58%$0.7027
AH$0.7192+2.35%vs close
Mkt Cap$238.29M
Float331.4M
O/S339.11M
Vol
$ Vol
RVOL
Inst Own43.0%
SI32.3%
Earnings
Dilution
Ocugen, Inc. logoNASDAQ:OCGN$0.7027-5.58%
Phase Distribution
14 lead-sponsored trials·6 active·3 completed
Phase 11
Phase 1/22
Phase 22
Phase 2/32
Phase 35
Not applicable2
(1 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting4
Completed3
Stopped2
Expanded access2
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Confirmatory Study of NeoCart in Knee Cartilage Repair

    NeoCart

    Articular Cartilage Defects in the Knee Joint

    Enrollment
    245
    Start
    May 2010
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT01066702
  • Phase 3
    Terminated

    Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

    Brimonidine Tartrate, Placebos

    Graft Versus Host Disease, Ocular Surface Disease +6

    Enrollment
    59
    Start
    Dec 2018
    Primary Completion
    Apr 2020
    Completion
    Apr 2020
    NCT03591874
  • Phase 3
    Completed

    Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

    Brimonidine Tartrate, Placebos

    Dry Eye

    Enrollment
    252
    Start
    Dec 2018
    Primary Completion
    Feb 2019
    Completion
    Feb 2019
    NCT03785340
  • Phase 3
    Active, not recruiting

    A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

    Sub-Retinal Administration of OCU400-301

    Retinitis Pigmentosa

    Enrollment
    140
    Start
    Jun 2024
    Primary Completion
    Feb 2027est.
    Completion
    Feb 2027est.
    NCT06388200
  • Phase 3
    Recruiting

    Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

    OCU410

    Dry Age-related Macular Degeneration

    Enrollment
    237
    Start
    Aug 2026
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2031est.
    NCT07770828
  • Phase 2/3
    Unknown status

    Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

    BBV152

    COVID-19

    Enrollment
    400
    Start
    Feb 2022
    Primary Completion
    Sep 2023est.
    Completion
    Oct 2023est.
    NCT05258669
  • Phase 2/3
    Active, not recruiting

    A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

    OCU410ST

    Stargardt Disease

    Enrollment
    51
    Start
    Aug 2023
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT05956626
  • Phase 2
    Completed

    NeoCart Phase 2 Clinical Trial

    NeoCart

    Articular Cartilage Damage

    Enrollment
    30
    Start
    Dec 2006
    Primary Completion
    Nov 2009
    Completion
    Mar 2014
    NCT00548119
  • Phase 2
    Completed

    Dry Eye Disease Study With Brimonidine

    Brimonidine, Brimonidine Mono Therapy

    Dry Eye

    Enrollment
    84
    Start
    Sep 2017
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT03418727
  • Phase 1/2
    Active, not recruiting

    Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

    OCU400 Low Dose, OCU400 Med Dose

    Retinitis Pigmentosa, Leber Congenital Amaurosis

    Enrollment
    22
    Start
    Jan 2022
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT05203939
  • Phase 1/2
    Active, not recruiting

    Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

    OCU410

    Geographic Atrophy

    Enrollment
    60
    Start
    Feb 2023
    Primary Completion
    Feb 2026
    Completion
    Feb 2030est.
    NCT06018558
  • Phase 1
    Recruiting

    Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

    OCU200

    Center Involved Diabetic Macular Edema, Diabetic Macular Edema

    Enrollment
    24
    Start
    Jan 2024
    Primary Completion
    Jul 2026est.
    Completion
    Jul 2026est.
    NCT05802329
  • Expanded access
    No longer available

    Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older

    BBV152

    COVID-19

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05541289
  • Expanded access
    No longer available

    Expanded Access Program for RP in Adults

    OCU400

    Retinitis Pigmentosa

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06574997
Search ClinicalTrials.gov for “Ocugen”